| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $153,228 | 9 | 100 |
| Gupta Ashoo | VP, Finance and Controller | 0 | $0 | 2 | $6,734 | $-6,734 |
| Kirn David | See Remarks | 0 | $0 | 1 | $19,258 | $-19,258 |
| Bizily Scott | Chief Legal Officer | 0 | $0 | 6 | $127,236 | $-127,236 |
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Over the last 12 months, insiders at 4D Molecular Therapeutics, Inc. have bought $0 and sold $153,228 worth of 4D Molecular Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at 4D Molecular Therapeutics, Inc. have bought $13.6M and sold $4.73M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 850,000 shares for transaction amount of $13.6M was made by VIKING GLOBAL INVESTORS LP (10 percent owner) on 2023‑05‑09.
| 2026-06-01 | Sale | Kirn David | See Remarks | 1,922 0.0038% | $10.02 | $19,258 | +4.13% | |
| 2026-03-20 | Sale | Gupta Ashoo | VP, Finance and Controller | 390 0.0008% | $8.61 | $3,358 | +11.44% | |
| 2025-12-20 | Sale | Gupta Ashoo | VP, Finance and Controller | 389 0.0008% | $8.68 | $3,377 | +0.35% | |
| 2025-12-16 | Sale | Bizily Scott | Chief Legal Officer | 1,635 0.0033% | $10.90 | $17,822 | -21.14% | |
| 2025-11-17 | Sale | Bizily Scott | Chief Legal Officer | 1,635 0.0034% | $10.59 | $17,315 | -15.80% | |
| 2025-10-24 | Sale | Bizily Scott | Chief Legal Officer | 2,678 0.0069% | $12.00 | $32,136 | -17.28% | |
| 2025-10-16 | Sale | Bizily Scott | Chief Legal Officer | 1,635 0.0035% | $10.17 | $16,628 | -6.54% | |
| 2025-10-09 | Sale | Bizily Scott | Chief Legal Officer | 2,408 0.0054% | $10.00 | $24,080 | -1.15% | |
| 2025-09-23 | Sale | Bizily Scott | Chief Legal Officer | 2,407 0.0054% | $8.00 | $19,256 | +23.52% | |
| 2024-09-16 | Sale | Bizily Scott | Chief Legal Officer | 500 0.001% | $16.33 | $8,165 | -70.51% | |
| 2024-08-19 | Sale | Bizily Scott | Chief Legal Officer | 500 0.001% | $15.00 | $7,500 | -66.96% | |
| 2024-07-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0044% | $27.11 | $47,443 | -79.07% | |
| 2024-07-11 | Sale | Bizily Scott | Chief Legal Officer | 1,996 0.0046% | $25.00 | $49,900 | -77.47% | |
| 2024-07-10 | Sale | Kirn David | Chief Executive Officer | 12,923 0.0268% | $22.49 | $290,598 | -74.92% | |
| 2024-07-01 | Sale | Bizily Scott | Chief Legal Officer | 4,248 0.0084% | $21.36 | $90,758 | -72.12% | |
| 2024-06-24 | Sale | Kirn David | Chief Executive Officer | 12,930 0.0248% | $23.10 | $298,711 | -72.75% | |
| 2024-06-17 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0034% | $23.71 | $41,494 | -72.65% | |
| 2024-05-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0034% | $25.45 | $44,541 | -68.47% | |
| 2024-04-16 | Sale | Bizily Scott | Chief Legal Officer | 1,750 0.0034% | $25.74 | $45,045 | -66.99% | |
| 2024-04-01 | Sale | Bizily Scott | Chief Legal Officer | 8,153 0.0173% | $31.78 | $259,102 | -63.98% |
| Kirn David | See Remarks | 1057231 2.0224% | $9.13M | 0 | 15 | |
| Gupta Ashoo | VP, Finance and Controller | 46914 0.0897% | $405,336.96 | 0 | 2 | |
| Bizily Scott | Chief Legal Officer | 3594 0.0069% | $31,052.16 | 0 | 25 | |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 4247914 8.1259% | $36.7M | 2 | 1 | <0.0001% |
| YAO TONY DUNG LING | director | 1060880 2.0294% | $9.17M | 1 | 0 | <0.0001% |
| SCHAFFER DAVID | director | 901215 1.7239% | $7.79M | 0 | 7 | |
| MILLIGAN JOHN F | director | 100000 0.1913% | $864,000.00 | 1 | 0 | <0.0001% |
| Kamal Fariborz | See Remarks | 4347 0.0083% | $37,558.08 | 1 | 0 | <0.0001% |
| Kim Robert Young | Chief Medical Officer | 1043 0.002% | $9,011.52 | 0 | 1 | |
| Chacko Jacob | director | 0 0% | $0 | 0 | 1 |
$27,082,337 | 104 | 6.73% | $392.87M | |
$70,111,730 | 78 | 26.02% | $525.72M | |
$16,169,789 | 40 | 7.44% | $476.44M | |
$1,323,997 | 34 | 0.21% | $428.22M | |
$2,303,314 | 30 | 166.84% | $419.47M | |
$112,238,340 | 19 | 39.16% | $448.14M | |
$2,516,932 | 19 | -15.78% | $426.54M | |
$22,365,077 | 19 | -27.47% | $466.66M | |
$133,809,976 | 13 | 31.29% | $461.33M | |
$65,355,913 | 13 | -3.42% | $416.01M | |
$57,263,116 | 11 | -8.37% | $451.16M | |
$105,345,724 | 9 | -19.24% | $499.4M | |
$13,043,783 | 8 | 732.82% | $521.78M | |
$15,652,720 | 6 | -4.77% | $472.82M | |
$12,035,408 | 5 | -37.54% | $406.03M | |
4D Molecular Therapeutics, Inc. (FDMT) | $88,549,962 | 5 | -16.91% | $451.67M |
$58,352 | 4 | -43.78% | $382.75M | |
$7,234,370 | 3 | -3.34% | $506.67M | |
$2,720,023 | 3 | -11.76% | $451.93M |
| Increased Positions | 89 | +67.94% | 17M | +42.68% |
| Decreased Positions | 52 | -39.69% | 3M | -7.65% |
| New Positions | 33 | New | 5M | New |
| Sold Out Positions | 14 | Sold Out | 220,351 | Sold Out |
| Total Postitions | 168 | +28.24% | 53M | +35.02% |
| Bvf Inc/Il | $33,886.00 | 8.42% | 4.63M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $33,403.00 | 8.3% | 4.56M | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $30,220.00 | 7.51% | 4.13M | -30,848 | -0.74% | 2025-09-30 |
| Blackrock, Inc. | $28,322.00 | 7.04% | 3.87M | -141,625 | -3.53% | 2025-09-30 |
| Vanguard Group Inc | $18,850.00 | 4.68% | 2.58M | -161,549 | -5.9% | 2025-09-30 |
| Novo Holdings A/S | $14,640.00 | 3.64% | 2M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $12,835.00 | 3.19% | 1.75M | -1,043 | -0.06% | 2025-09-30 |
| Federated Hermes, Inc. | $11,674.00 | 2.9% | 1.59M | -72,506 | -4.35% | 2025-09-30 |
| Millennium Management Llc | $8,414.00 | 2.09% | 1.15M | -334,323 | -22.53% | 2025-09-30 |
| Armistice Capital, Llc | $8,023.00 | 1.99% | 1.1M | +796,000 | +265.33% | 2025-09-30 |